Navigation Links
ChemoCentryx Reports Clinical Efficacy for CCX354, a Novel CCR1 Inhibitor in a Phase II Study in Patients with Rheumatoid Arthritis
Date:11/8/2011

pies. RA is estimated to affect more than two million people in the U.S. and is a leading cause of morbidity, disability and reduced work ability. The exact cause of RA is unknown, but is believed to reflect the body's immune system attack on the synovium, the tissue that lines the joints.

CCX354 is one of four drug candidates that have been discovered and developed by ChemoCentryx that are also part of an alliance between the Company and GlaxoSmithKline (GSK).  Successful completion of CARAT-2 triggered GSK's option rights under the collaboration agreement, and ChemoCentryx expects GSK's decision whether to exercise its option to obtain a license to further develop and commercialize CCX354 by the end of 2011.

About ChemoCentryxChemoCentryx, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics that target the chemokine and chemoattractant systems in order to treat autoimmune diseases, inflammatory disorders and cancer. The chemokine system is a biological network that regulates inflammation via a collection of secreted chemokine molecules, or ligands, and their specific cell surface receptors. Based on its proprietary drug discovery and drug development platform, ChemoCentryx has generated multiple clinical and preclinical-stage programs, each targeting distinct chemokine and chemoattractant receptors with different small molecule compounds. ChemoCentryx's most advanced drug candidate, CCX282-B (Traficet-EN, now designated GSK1605786, also known as GSK'786), a specific CCR9 inhibitor, completed a multi-national clinical trial, called PROTECT-1, in patients with moderate-to-severe Crohn's disease, where it demonstrated the ability to induce a clinical response and to maintain clinical remission, and is now in Phase III clinical development. ChemoCentryx's lead independent drug candidate, CCX140-B, a CCR2 inhibitor, has been shown to be safe and well tolerated w
'/>"/>

SOURCE ChemoCentryx, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. ChemoCentryx Initiates Phase II Clinical Trial for CCX168, a Novel Small Molecule C5aR Antagonist for the Treatment of Vasculitis
2. ChemoCentryx Reports Novel CCR2 Antagonist Significantly Improves Kidney Function and Hyperglycemia in Models of Type 2 Diabetes
3. ChemoCentryx Initiates Phase I Clinical Trial of CCX832, the First Small Molecule Inhibitor of ChemR23
4. ChemoCentryx to Present at the 29th Annual J.P. Morgan Healthcare Conference
5. ChemoCentryx Reports Positive Phase I Results for CCX168, a Novel C5aR Antagonist, at the Annual American College of Rheumatology Meeting (ACR)
6. ChemoCentryx Reports One-Year Results from PROTECT-1 Study Demonstrating Traficet-ENs Effectiveness in Treating Patients with Crohns Disease at the United European Gastroenterology Federation (UEGW) Meeting
7. ChemoCentryx Reports Positive Results and Completion of Phase I Clinical Studies of Novel CCR2 Antagonist, CCX140, at the European Association for the Study of Diabetes (EASD)
8. ChemoCentryx Reports that Traficet-EN Maintains Remission in Crohns Disease at the Digestive Disease Week (DDW) 2010 Conference
9. ChemoCentryx Initiates Clinical Trial of CCX168, A Novel Small Molecule C5aR Antagonist for the Treatment of Inflammatory and Autoimmune Diseases
10. ChemoCentryx Initiates Phase 2 Clinical Trial of CCX354 for the Treatment of Rheumatoid Arthritis
11. ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-ENs Effectiveness in Maintaining Remission in Patients with Crohns Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... 1, 2015 The global ... basis of sectors, products & services and application. And ... with the increasing demand of advanced drugs for ... propel the growth for bioinformatics market. The implementation ... is known as bioinformatics. Decreasing cost of DNA ...
(Date:9/1/2015)... DUBLIN , Aug. 31, 2015 ... the addition of the "Introduction to Veterinary ... to their offering. This course ... a good introduction to those concerned with Veterinary ... experienced personnel who reqire a better understanding of ...
(Date:9/1/2015)... , Sept. 1, 2015  Abbott (NYSE: ABT ... a multi-center, randomized trial comparing the safety and effectiveness ... ® , Abbott,s market-leading, permanent drug eluting stent. ... Japan and enrolled 400 people with ... disease. The results will be featured at a late-breaking ...
Breaking Medicine Technology:Global Bioinformatics Market Valued at Over $1.3 Billion in 2013 and is Expected to Grow at CAGR of 20.3% From 2014 to 2020: Hexa Research 2Global Bioinformatics Market Valued at Over $1.3 Billion in 2013 and is Expected to Grow at CAGR of 20.3% From 2014 to 2020: Hexa Research 3Global Bioinformatics Market Valued at Over $1.3 Billion in 2013 and is Expected to Grow at CAGR of 20.3% From 2014 to 2020: Hexa Research 4Introduction to Veterinary Pharmacovigilance Seminar (London, UK - September 23-24) 2Abbott Announces Positive Results of Its Naturally Dissolving Stent from ABSORB Japan Study 2Abbott Announces Positive Results of Its Naturally Dissolving Stent from ABSORB Japan Study 3Abbott Announces Positive Results of Its Naturally Dissolving Stent from ABSORB Japan Study 4
... has released an updated AutoLabel solution with enhanced customized ... virtually 100% of medications have a scan-ready bar code ... AutoLabel is a complete barcoding solution that provides color-coded ... improve patient safety at the bedside. New features include ...
... ("CTI") (NASDAQ and MTA: CTIC) announced that final results ... relapsed or refractory acute myeloid leukemia ("AML") was selected ... of Hematology ("ASH") Annual Meeting, which will be held ... Jorge Cortes, M.D., of The University of ...
Cached Medicine Technology:Talyst Updates Its AutoLabel® Solution 2Tosedostat OPAL Study Final Results Selected for Oral Presentation at the 2011 American Society of Hematology (ASH) Annual Meeting 2Tosedostat OPAL Study Final Results Selected for Oral Presentation at the 2011 American Society of Hematology (ASH) Annual Meeting 3Tosedostat OPAL Study Final Results Selected for Oral Presentation at the 2011 American Society of Hematology (ASH) Annual Meeting 4
(Date:9/1/2015)... (PRWEB) , ... September 01, 2015 , ... Horizon Blue ... the 50 Best Companies for Latinas in the LATINA Style 50 Report that recognizes ... , For 2015, Horizon BCBSNJ climbs from number 24 to 21 ...
(Date:9/1/2015)... ... September 01, 2015 , ... Splashtop Inc. ... for Remote Support , a solution optimized for MSPs and IT professionals looking ... renewal prices and inadequate customer services of existing remote support solution, many MSPs ...
(Date:9/1/2015)... ... September 01, 2015 , ... ... that Edge Information Management has been granted continued accreditation based on a ... , “Achieving and maintaining this accreditation takes the involvement and dedication ...
(Date:9/1/2015)... , ... September 01, 2015 , ... ... the release of version 5.2 of the FirstSpirit Content Management System with new ... With the new version of FirstSpirit, companies will be well on their way ...
(Date:9/1/2015)... D.C. (PRWEB) , ... September 01, 2015 , ... Two ... better cross cultural relations through food and dining. , Recently named “the next ... and Luigi Diotaiuti are known for telling the whole story behind food and reclaiming ...
Breaking Medicine News(10 mins):Health News:Horizon Blue Cross Blue Shield of New Jersey Named One of the 50 Best Companies for Latinas by Latina Style Magazine 2Health News:Horizon Blue Cross Blue Shield of New Jersey Named One of the 50 Best Companies for Latinas by Latina Style Magazine 3Health News:Splashtop Launches Splashtop Business for Remote Support, the Simple, Reliable, and Cost-Effective Solution for MSPs and IT Professionals 2Health News:Splashtop Launches Splashtop Business for Remote Support, the Simple, Reliable, and Cost-Effective Solution for MSPs and IT Professionals 3Health News:Splashtop Launches Splashtop Business for Remote Support, the Simple, Reliable, and Cost-Effective Solution for MSPs and IT Professionals 4Health News:Edge Information Management Granted Continued NAPBS Accreditation 2Health News:Edge Information Management Granted Continued NAPBS Accreditation 3Health News:e-Spirit boosts Corporate Content Cloud initiative with release of FirstSpirit 5.2 2Health News:e-Spirit boosts Corporate Content Cloud initiative with release of FirstSpirit 5.2 3Health News:Chefs Amy Riolo and Luigi Diotaiuti Embark on Culinary Diplomatic Quest to Build Bridges through Global Cuisine 2Health News:Chefs Amy Riolo and Luigi Diotaiuti Embark on Culinary Diplomatic Quest to Build Bridges through Global Cuisine 3Health News:Chefs Amy Riolo and Luigi Diotaiuti Embark on Culinary Diplomatic Quest to Build Bridges through Global Cuisine 4
... men with prostate cancer would rather find out sooner than ... for prostate cancer using the prostate-specific antigen test. But since PSA ... for doctors to know what a high reading is and what ... higher levels have to undergo repeated biopsies to determine whether they ...
... study sheds light on the theory that aging is associated ... suggest the gene responsible for shortening the ends of chromosomes ... measured the length of the end of the chromosomes, known ... random sample of families living in northern Belgium. Telomere length ...
... for kids in the United Kingdom, finds a new ... preschoolers. ,The study involved 78 children who were 3 ... their total energy expenditure, along with their amount of ... were spending only about 20 to 25 minutes a ...
... meeting of the Radiological Society of North America shows ... stones in the kidneys, bladders and urinary tracts of ... MDCTU ) scans can be performed using helical CT ... angles. Patients are given a contrast dye that allows ...
... the last half century, and officials at the ... be diagnosed with it this year.,The study, which analyzed ... ages of 30 and 50,// found what the researchers ... tanning can be dangerous to healthy skin. ,Melanoma ...
... suggests that aerobic exercise alone is best for lowering blood ... of a difference when it comes time to face the ... during periods of vigorous exertion, but exercise as a regular ... at whether the type of exercise// people engaged has made ...
Cached Medicine News:Health News:CT Scans Said to Accurately Detect Small Cancers 2Health News:Solarium use is associated with an increased risk of skin cancer 2Health News:Aerobics- right choice for Cutting Blood Pressure 2
... ergonomic chairs with concave seats ... support • Select options like ... and glides. • BTT/1P chairs ... environments: industry, education, laboratory, clean ...
... with concave seats and standard-sized ... Select options like seats, backrests, ... • BTT/1P chairs are recommended ... education, laboratory, clean room, static ...
... chairs with concave seats and large ... options like seats, backrests, armrests, and ... BE Series for top performance in ... education, laboratory, clean room, static control, ...
... ergonomic chairs with concave seats and ... Select options like seats, backrests, armrests, ... the BE Series for top performance ... industry, education, laboratory, clean room, static ...
Medicine Products: